Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Plasma N-glycans in color… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Plasma N-glycans in colorectal cancer risk

Artikel i vetenskaplig tidskrift
Författare M. Doherty
E. Theodoratou
I. Walsh
Barbara Adamczyk
H. Stockmann
F. Agakov
M. Timofeeva
I. Trbojevic-Akmacic
F. Vuckovic
F. Duffy
C. A. McManus
S. M. Farrington
M. G. Dunlop
M. Perola
G. Lauc
H. Campbell
P. M. Rudd
Publicerad i Scientific Reports
Volym 8
ISSN 2045-2322
Publiceringsår 2018
Publicerad vid Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi
Språk en
Länkar https://doi.org/10.1038/s41598-018-...
Ämnesord ovarian-cancer, acetylglucosaminyltransferase v, structural, requirements, glycoprofiling platform, serum glycoproteins, glycosylation, igg, disease, glycome, arthritis, Science & Technology - Other Topics
Ämneskategorier Cancer och onkologi, Medicinsk cellbiologi

Sammanfattning

Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma W-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, W-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?